Since many AMPK pharmacological activators such as metformin, berberine, resveratrol, and thiazolidinediones (TZDs), have been shown to lower levels of blood glucose and lipids, and used in clinic for the treatment of type 2 diabetes and obesity, AMPK is a well-received therapeutic target for metabolic diseases [6,7]. The gene discussed is PRKAA1; the disease is metabolic disease.